Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of October 2021, with a specific reporting date of October 12, 2021. The document serves as a transaction notification regarding dealings in the company's ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs).
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively reports on specific share transactions:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Type: Acquisition of shares via dividend reinvestment within an Individual Savings Account (ISA).
- Transaction Date: October 8, 2021.
- Transaction Price: £14.0526 per share.
- Volumes:
- Mr. D Redfern (Chief Strategy Officer): 30 shares.
- Ms. V Whyte (Company Secretary): 26 shares.
- Exchange: London Stock Exchange (XLON).
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It strictly documents routine compliance notifications for internal share acquisitions resulting from dividend reinvestment plans.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or unusual items. The document is a regulatory disclosure of insider trading activity required under the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the total number of shares held by Mr. D Redfern and Ms. V Whyte post-transaction to assess overall insider ownership levels.
- Confirm the dividend payment date of October 7, 2021, to validate the timing of the reinvestment.
- Check the prevailing market price of GSK shares on October 8, 2021, to ensure the transaction price of £14.0526 was consistent with market rates.
- Review subsequent Form 6-K filings to monitor any further changes in PDMR holdings.